MyMD Pharmaceuticals Enrolls First Patient in Phase II Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan

MyMD Pharmaceuticals, Inc. announced that the first patient has been enrolled in the company’s Phase II clinical trial of lead candidate MYMD-1, an oral immune regulator drug, as a therapy for delaying aging and expanding healthy lifespan.